Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Research & Development (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Research & Development for 12 consecutive years, with $216000.0 as the latest value for Q2 2025.

  • Quarterly Research & Development fell 79.27% to $216000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $378000.0 through Dec 2025, down 85.47% year-over-year, with the annual reading at $1.3 million for FY2025, 52.11% down from the prior year.
  • Research & Development for Q2 2025 was $216000.0 at Aytu Biopharma, up from $162000.0 in the prior quarter.
  • The five-year high for Research & Development was $4.8 million in Q2 2021, with the low at $162000.0 in Q1 2025.
  • Average Research & Development over 5 years is $1.5 million, with a median of $856000.0 recorded in 2023.
  • The sharpest move saw Research & Development skyrocketed 1464.69% in 2021, then tumbled 85.71% in 2023.
  • Over 5 years, Research & Development stood at $4.5 million in 2021, then plummeted by 61.79% to $1.7 million in 2022, then tumbled by 69.53% to $521000.0 in 2023, then rose by 0.19% to $522000.0 in 2024, then crashed by 58.62% to $216000.0 in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $216000.0, $162000.0, and $522000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.